Kinnate Biopharma Inc.

NASDAQ:KNTE

2.65 (USD) • At close April 3, 2024
Bedrijfsnaam Kinnate Biopharma Inc.
Symbool KNTE
Munteenheid USD
Prijs 2.65
Beurswaarde 124,990,960
Dividendpercentage 0%
52-weken bereik 1.04 - 7.185
Industrie Biotechnology
Sector Healthcare
CEO Mr. Nima Farzan M.B.A.
Website https://www.kinnate.com

An error occurred while fetching data.

Over Kinnate Biopharma Inc.

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule

Vergelijkbare Aandelen

Vaxart, Inc. logo

Vaxart, Inc.

VXRT

0.885 USD

Adicet Bio, Inc. logo

Adicet Bio, Inc.

ACET

1.48 USD

Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc.

PRAX

54.02 USD

Rallybio Corporation logo

Rallybio Corporation

RLYB

1.1 USD

IRadimed Corporation logo

IRadimed Corporation

IRMD

44.89 USD

RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc.

RAPT

1.83 USD

Nuvalent, Inc. logo

Nuvalent, Inc.

NUVL

86.25 USD

Day One Biopharmaceuticals, Inc. logo

Day One Biopharmaceuticals, Inc.

DAWN

14.2 USD

Alpha Tau Medical Ltd. logo

Alpha Tau Medical Ltd.

DRTS

2.275 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)